Abstract:
In the continued effort to better diagnose disease and predict therapeutic outcomes, researchers around the world have made significant efforts to validate new biomarkers and develop probes to image these in patients. Furthermore, to better understand the biological basis of disease in vivo, other researchers have been building new probes and biomarkers to report on biological processes at the cellular and tissue level strictly for pre-clinical research. While both of these areas have seen rapid progression over the past decade, there is still significant progress that can be made.
To support the ever changing needs of imaging researchers, Carestream Molecular Imaging can provide seven molecular imaging modalities in just two instruments. The In Vivo MS FX PRO can be utilized in fluorescence, luminescence, radio-isotopic, and radiographic (X-ray imaging) modes, and the Albira system can image subjects in PET, SPECT, and CT modes. By utilizing both high throughput 2D molecular imaging technology, coupled with quantitative 3D imaging technology for the appropriate research questions, researchers will be able to better more rapidly and accurately evaluate new probes and biomarkers in small animal models. In this webinar, we will provide real world research examples of evaluating new molecular imaging probes, and studying the application of existing probes in small animal models.